On the Floor of the NYSE: Talking AI and the Future of Cancer Treatment

Last week, I had the incredible opportunity to be back at the New York Stock Exchange to interview the CEO of Lantern Pharma for New to The Street. Lantern is doing something truly groundbreaking: using artificial intelligence to dramatically speed up cancer drug development — turning what used to take years into mere months.

In our conversation, we explored how their AI platform, RADR®, is helping scientists predict which patients will benefit most from specific therapies, cutting down trial timelines and accelerating hope for patients. We also talked about the company’s recent success with its LP-184 clinical trial and the exciting momentum behind its spinoff, Starlight Therapeutics, focused on brain and CNS cancers.

Standing there on the iconic NYSE floor, hearing how AI is reshaping oncology in real time, reminded me why I love this work — storytelling at the intersection of innovation, science, and human impact.

Watch the full interview here.